CSL Vifor Managed Access Programs
In circumstances where patients have exhausted approved treatment options and are not eligible for clinical trials, CSL Vifor supports early access to investigational drugs via Managed Access Programs which describe how healthcare professionals can submit requests for access to investigational drugs on behalf of the patients in their care.
Learn More About These ProgramsSearch Results
192 results found-
The evidence from Nordic countries underscores the importance of enhanced influenza vaccines (EIVs) for adults aged 65 and older, and suggests the need for countries across Europe to adopt or expand policies supporting their use.
https://newsroom.csl.com/2025-10-21-Enhanced-Influenza-Vaccines-Provide-Essential-Protection-for-Older-Adults-CSL-Seqirus-Presents-New-Evidence-Supporting-Broader-Adoption-Across-Europe -
LIVING WITH IRON DEFICIENCY SINCE THE AGE OF 16
https://www.csl.com/patients-public-health/iron-deficiency/iron-deficiency-patient-stories/iron-deficiency-andy -
ST. GALLEN, SWITZERLAND, March 19, 2024 / PRNewswire / -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.
https://newsroom.csl.com/2024-03-19-Ferinject-R-approved-by-Health-Canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure -
Her research explores how, as we age, our T-cells become less effective at fighting acute viral infections and less flexible in responding to novel viruses.
https://newsroom.csl.com/2025-10-29-Australian-scientists-awarded-2-5-million-CSL-Centenary-Fellowships-to-advance-lifelong-immunity-research-and-AI-designed-proteins -
It is not known if ANDEMBRY is safe and effective in children under 12 years of age.
https://newsroom.csl.com/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start -
FLUAD is a vaccine that helps protect people aged 65 years and older from the flu.
https://newsroom.csl.com/2025-10-17-CSL-Seqirus-Presents-Latest-Research-Across-Leading-Seasonal-Influenza-Vaccine-Portfolio-at-ESWI-2025 -
Australia's onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,...
https://newsroom.csl.com/ -
IgA nephropathy is a condition with an average age at diagnosis of around 40 years.
https://newsroom.csl.com/2025-05-23-Englands-NICE-recommends-FILSPARI-R-sparsentan-as-a-treatment-option-for-IgA-nephropathy -
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please let us know.
https://www.csl.com/careers/eeo-statement -
Answers to the most frequently asked questions about Clinical Trials.
https://www.csl.com/research-and-development/clinical-studies/clinical-studies-faqs